SAN DIEGO, Nov. 13 /PRNewswire-FirstCall/ -- Somaxon Pharmaceuticals, Inc. today announced that it will present at the following two conferences:
BIOCOM San Diego Investor Conference Wednesday, November 15, 2006, at 11:40 a.m. PT (2:40 p.m. ET) Presenter: Ken Cohen, President and Chief Executive Officer San Diego Marriott Del Mar, San Diego, CA 2006 Credit Suisse Healthcare Conference Friday, November 17, 2006, at 9:30 a.m. PT (12:30 p.m. ET) Presenter: Ken Cohen, President and Chief Executive Officer Arizona Biltmore Resort, Phoenix, AZ
A live webcast of the presentations will be available in the Investor Relations section of the company’s website under Event Scheduler at www.somaxon.com. The webcasts will be archived and accessible for at least 14 days.
About Somaxon Pharmaceuticals
Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon’s lead product candidate, SILENOR(TM) (doxepin HCl), is in Phase 3 clinical trials for the treatment of insomnia. Nalmefene HCl is in a Phase 2/3 clinical trial for pathological gambling and has completed a pilot Phase 2 trial for smoking cessation. Acamprosate Ca, a potential treatment for movement disorders, is currently in formulation development.
For more information, please visit the company’s web site at www.somaxon.com.
Contacts: Meg McGilley Chief Financial Officer (858) 480-0402 Rob Whetstone PondelWilkinson, Inc. (310) 279-5963
Somaxon Pharmaceuticals, Inc.
CONTACT: Meg McGilley, Chief Financial Officer of Somaxon Pharmaceuticals,Inc., +1-858-480-0402; or Rob Whetstone of PondelWilkinson, Inc.,+1-310-279-5963, for Somaxon Pharmaceuticals, Inc.
Web site: http://www.somaxon.com/
